Rabies immunoglobulins (RIG) provide immediate passive immunity by neutralizing the rabies virus at the wound site, buying time for the active immune response from the vaccine to develop. In the Human Rabies Vaccine Market, Human Rabies Immunoglobulin (HRIG) holds the largest share (62%) due to its superior safety profile and efficacy. Derived from the plasma of hyperimmunized human donors, HRIG carries a very low risk of allergic reactions (including anaphylaxis) and no risk of serum sickness. It is the preferred choice for PEP in high-income countries and for category III exposures in any setting.

Equine Rabies Immunoglobulin (ERIG) is the fastest-growing segment, driven by its cost-effectiveness and increasing availability in resource-limited, high-burden countries. ERIG is produced by hyperimmunizing horses and purifying the antibodies. While it is associated with a higher risk of adverse reactions (including serum sickness in up to 40% of recipients), it is significantly more affordable (up to 10-20x cheaper) than HRIG. Its affordability makes it the only feasible option for many public health systems in Asia and Africa.

Recent advancements in purification techniques (e.g., pepsin-digested and purified ERIG, F(ab')2 fragments) have reduced the risk of adverse reactions, further boosting its adoption. The growing acceptance of ERIG by WHO and other global health bodies, coupled with its critical role in PEP accessibility, makes it an essential and rapidly expanding segment of the RIG market.

Do you think the high cost of HRIG will always limit its use to high-income countries, or will next-generation manufacturing technologies eventually make it affordable enough for widespread use in endemic regions?

FAQ

What is the difference between Human Rabies Immunoglobulin (HRIG) and Equine Rabies Immunoglobulin (ERIG)? HRIG is derived from human plasma, has a low risk of adverse reactions (serum sickness <1%, anaphylaxis rare), is the preferred product in high-income countries, but is very expensive ($1,000-5,000 per course). ERIG is derived from horse plasma, has a higher risk of adverse reactions (serum sickness 5-40%, anaphylaxis 1-2 per 10,000), is the only affordable option in many low-income countries, and is significantly cheaper ($50-200 per course). Both are effective when administered correctly. The WHO recommends HRIG when available, but ERIG is an acceptable alternative. To reduce adverse reactions, purified ERIG products (F(ab')2 fragments) are now available.

What is serum sickness and how is it managed? Serum sickness is a type III hypersensitivity reaction that occurs 5-10 days after administration of ERIG, caused by the immune system reacting to the equine proteins. Symptoms include: fever, rash (hives), joint pain and swelling (arthralgia), lymphadenopathy, and in severe cases, kidney involvement. Management includes: antihistamines for itching, non-steroidal anti-inflammatory drugs (NSAIDs) for joint pain, and corticosteroids for severe or persistent symptoms. Serum sickness is typically self-limiting and resolves within days to weeks. The risk is significantly lower with newer, purified ERIG preparations (F(ab')2 fragments) compared to older whole-serum products. Patients receiving ERIG should be educated about the symptoms of serum sickness and advised to seek medical attention if they occur.

#HRIG #ERIG #RabiesImmunoglobulin #PassiveImmunity #SerumSickness #PEP #GlobalHealthEquity